Sun Pharmaceutical has got USFDA nod for its abbreviated new drug application (ANDA) to sell levetiracetam injection, which is a generic version of Keppra jab.

This generic levetiracetam injection., 100 mg /ml packaged in 500 mg / 5 ml single use vials, is equivalent to UCB`s Keppracy Injection 100 mg/ml.

The 12-monthly sale of levetiracetam injection in the US market is estimated at $85 million.

levetiracetam injection is prescribed as adjunctive therapy for treating partial onset seizures in adults suffering from epilepsy.

Sun Pharma expects to enter the market soon with this product.

On June 02, Sun Pharmaceuticals Industries Ltd has refused a $215 million offer from US-based banker and financial advisor Guggenheim Securities Llc to get hold of its 36% equity stake in Israel's Taro Pharma.

At 12:59 p. m., the shares of the company surged Rs 9.05 at Rs 1,709.20 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 1846 and a low of Rs 1103 on BSE.

Current EPS & P/E ratio stood at 65.23 and 26.27 respectively.